Suven Pharmaceuticals Ltd saw its shares jump over 7% in morning trade after posting impressive Q3 FY25 results. As of 9:32 AM, the shares were trading 7.62% higher at Rs 1,128.05.
The company reported a massive 77.1% year-on-year (YoY) increase in net profit, reaching ₹82.9 crore compared to ₹46.8 crore in the same period last year. Revenue also surged 39.8% YoY to ₹307.2 crore from ₹219.8 crore in Q3 FY24.
At the operational level, EBITDA soared 78.2% YoY to ₹117.8 crore, with EBITDA margins expanding significantly to 38.4% from 30.1% in Q3 FY24. Strong performance in the pharma CDMO segment, which recorded a 101% YoY increase, played a key role in driving growth. Gross margins stood at 71.5%, while adjusted EBITDA margins reached 38.7%.
In the first nine months of FY25, Suven Pharma incurred a capital expenditure of ₹938 million and generated ₹1.33 billion in free cash flow. The company’s robust cash and bank balance of ₹2.82 billion reflects its strong financial standing.
Additionally, the pharma CDMO segment witnessed a twofold YoY rise in RFQs for 9M FY25, indicating continued demand. Suven added two new molecules to its portfolio, bringing total active phase 3 projects to 15, covering nine molecules. Meanwhile, the specialty chemicals (SpecChem) CDMO segment showed signs of recovery after a weak Q2, with further improvement expected.
Suven Pharmaceuticals’ shares opened at ₹1,070.00, reaching a high of ₹1,134.85 and a low of ₹1,070.00. The stock remains strong, nearing its 52-week high of ₹1,360.00, significantly above its 52-week low of ₹598.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
